Clinical evaluation of the surgical and endoscopic treatment of morbid obesity by Schouten, R.
  
 
Clinical evaluation of the surgical and endoscopic
treatment of morbid obesity
Citation for published version (APA):
Schouten, R. (2011). Clinical evaluation of the surgical and endoscopic treatment of morbid obesity.
[Maastricht: Universiteit Maastricht.
Document status and date:
Published: 01/01/2011
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.




Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
 C h a P t e r  5




The main purpose of this thesis was to describe the clinical results of bariatric surgery.
Traditionally, bariatric operations have been subdivided into restrictive and malabsorptive 
procedures. The history of bariatric surgery began with a range of malabsorptive 
procedures which have been either abandoned because of severe side effects or 
have been considerably modified [1]. Restrictive procedures have less severe side 
effects because the gastrointestinal tract remains intact and the digestive functionality 
unchanged. As a result, vitamin and mineral deficiencies are rare [2-5]. Although 
a wide range of procedures is available nowadays there are certainly a number of 
standard bariatric procedures. Laparoscopic adjustable gastric banding (LAGB) and 
(laparoscopic) vertical banded gastroplasty (VBG) are purely restrictive in nature while 
biliopancreatic diversion (BPD) and duodenal switch (DS) result in some restriction 
but their effect is largely based on malabsorption. The roux-en-y gastric bypass 
(RYGB) procedure combines a slight malabsorption with restriction while the recently 
popularized gastric sleeve resection (GSR) is merely a restrictive procedure. These 
standard bariatric procedures all have their own specific effect on the gastrointestinal 
tract, intestinal hormone levels and vitamin and mineral status. For example, the effect 
of RYGB is partially caused by the duodenal bypass effect. Excluding the duodenum 
from nutrients improves glucose homeostasis by itself [6]. The positive effect on weight 
loss by the delivery of undigested nutrients to the more distal bowel in Type 2 diabetes is 
another theory proven in several studies [7-9]. The gastric fundus resection in GSR plays 
an important role in the postoperative weight loss because of the decrease in ghrelin 
production [10]. Although in recent years much knowledge has been gained through 
intensive research, the exact working mechanisms of bariatric procedures are not yet 
fully understood. There is however extensive evidence that bariatric surgery does what 
it is designed to do. Independent of the type of procedure it results in sufficient and long 
term weight loss and a decrease in obesity-related comorbidities [11-13]. According to 
the meta-analysis of Buchwald et al., weight loss varies from a mean excess weight 
loss (%EWL) of 47.5% after LAGB to 70.1% after BPD and DS. Decrease in obesity-
related comorbidities is in proportion with weight loss [13]. However, differences in 
weight loss decline in the postoperative years. After 3 years, weight loss after LAGB is 
49.4% EWL compared to 62.2% EWL after RYGB, according to a meta-analysis of Garb 
et al. [14]. Long term results described by O’Brien et al. indicate that LAGB and RYGB 
have comparable results after 10 years with an EWL of 59% and 52%, respectively [15]. 
The same accounts for the postoperative quality of life. Improvement in quality of life 
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after bariatric surgery is comparable after LAGB, VBG and RYGB [16-18]. Quality of life 
improvement is long lasting and solely dependent on weight loss as reported by many 
authors [16, 17, 19-26].  This is described and confirmed in paragraph 2.2; significant 
correlations between weight loss and improvement of 8 of the 13 HRQoL domains were 
found independent of the type of procedure. Because results of weight loss, decrease 
in comorbidities and improvement in quality of life are comparable after the different 
procedures the focus in bariatric surgery should not be exclusively on these parameters. 
More attention should be given on the distinguishing features of the different types of 
operations. Important aspects are the long term complications and re-operations which 
are specifically addressed in the present thesis. 
Results of  LAGB
In chapter 2.1, the long term results of LAGB are described. An EWL of 55% after 2 
years and 54% after 7 years was found with an accompanying significant decrease in 
obesity-related comorbidities. This is consistent with the literature findings of 56% to 
62% EWL after a follow up period of at least 5 years [27-29]. However, this success 
is overshadowed by frequent long term complications usually leading to revisional 
surgery. After LAGB, 44% of patients underwent a re-operation during follow up due to 
band-related complications. Frequently encountered problems were pouch dilatation 
(21%), slippage (17%), band erosion (4%) and leakage (2%). Although the percentages 
of complications appear to be high they are consistent with the literature. Band erosion 
occurs in 0% to 14% [29-33], pouch dilatation in 8% to 24% [30, 33-35], slippage in 2% 
to 24% [30, 33-35] and band leakage or related tubing problems in 1% to 38% [33-35]. 
Because of these complications frequent re-operations are necessary after LAGB with 
a range in the literature of 2% to 80% [34, 36-43]. In chapter 2.1 a re-operation rate of 
44% after 7 years is described. Mean time between the primary operation and the re-
operation because of complications was 3 years. However, the number of re-operations 
is declining over the last years. Several mechanisms are responsible for the decrease 
in complications and re-operations. First, the surgical technique of placing the band has 
changed from perigastric to pars flaccida. Band slippages and pouch dilatation have 
decreased significantly from 29% to 4% after introduction of the pars flaccida technique 
in our clinic. In two randomized studies from Weiner et al. and O’Brien et al. the pars 
flaccida technique was demonstrated to be a safer technique with less complications, 
especially due to a decrease in (posterior) slippages from 16% to 4% and from 4% to 0% 
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[44, 45]. Second, many technical improvements have been made to the band itself like 
low pressure – high volume bands instead of high pressure- low volume bands resulting 
in a decrease in re-operation rate because of less slippages and possibly less erosions 
[46-49]. With use of the former, slippage rates as low as 2% have been reported after 
a follow up period of 2 years [50]. However, these encouraging numbers have to be 
brought into perspective because the third and most important reason for the reported 
differences in complications and re-operations after LAGB is the completeness and 
duration of follow up. In the literature, follow up period is highly variable with subsequent 
differences in re-operation rate, e.g. 3.3% after 2 years and 58% after 7 years [30, 51]. 
Apart from the duration the completeness of follow up is also very important. The re-
operation rate in a retrospective study by Christou et al. was 16.1% after 3 years but 
only one third of patients were available for follow up [52]. In a case-controlled study 
by Cottam et al. the re-operation rate was 53% in the first year decreasing to 0% in the 
third year. However, follow up after 3 years was only 25% [53]. In chapter 2.1, mean 
time between the primary operation and the re-operation because of complications was 
3 years. These results emphasize that a follow up of a reasonable patient population of 
3 years and preferably 5 years is necessary for a reliable estimation of the re-operation 
rate.
In case of a failure after LAGB the first option is to preserve the band by performing a 
refixation or replacement. In the present thesis this option is described in chapter 3.2. 
Weight loss after laparoscopic refixation of the band was a decrease in BMI of 4.5 kg/
m² after a mean follow up period of 34 months. The late re-operation rate because of 
complications was 5%. Results of a refixation or replacement of the band have been 
variable in the literature. The re-operation rate is 0% to 45% while weight results varied 
from a weight gain of 2.4 BMI points to a weight loss of 5.8 BMI points [54-65]. In 
order to compare refixation or replacement of the band with other revisional options a 
literature review is described in chapter 3.3. In the literature, results after conversion to 
RYGB in case of LAGB failure seem to be better. The re-operation rate after conversion 
to RYGB was 0% to 20%. Weight loss varied with a decrease in BMI between 6.1 to 
13.2 kg/m² [55, 66-75]. The conversion to BPD or DS leads to more complications, 
especially procedure-specific nutritional problems, while weight loss is not significantly 
better [76-79]. Only in case of band erosion the conversion to BPD might be a feasible 
option because the procedure can be performed away from the eroded proximal gastric 
tissue. The preliminary results of conversion to GSR are encouraging [80-84] but longer 
follow up is necessary before this option can be considered as a feasible alternative. 
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In conclusion, patients with satisfying weight loss after LAGB suffering from a pure 
technical failure benefit from refixation or replacement of the band. For patients with 
poor weight loss or non-compliance a conversion to RYGB is the best option. 
Results of  VBG
In chapter 2.1 the long term results of VBG are described. This restrictive procedure 
results in an EWL of 69% after a mean follow up of 7 years. Weight loss more than 5 
years after VBG varies in the literature from 30% to 59% EWL [27, 28, 85]. However, this 
apparent success of VBG is overshadowed by a high percentage of failures. Frequent 
complications necessitating a re-operation are stapler line dehiscence (51%) and 
anastomotic stenosis (9%). This ranges in literature from 29% to 50% [86-89] and from 
14% to 40% [86-88], respectively. Because of several other long term complications 
like pouch dilatation and weight loss failure the percentage of re-operations after VBG 
is even higher. Re-operation percentages in the literature range from 10% to 79% [85, 
86, 89-92] and the present thesis confirms this high failure rate (65%) after a follow up 
period of 7 years. Based on the literature findings and the present thesis it can be stated 
that VBG is a successful operation in terms of weight loss, also in a long term manner, 
but the failure rate is too high.
In case of failure after VBG several revisional procedures are possible. Although not 
investigated in the present thesis it has been indisputably proven in literature that 
re-doing the procedure (re-VBG) leads to poor results and a re-re-operation rate of 
up to 68% [86, 87, 93-96]. Therefore, a conversion to another bariatric procedure is 
always necessary in the case of VBG failure. Results of the conversion from VBG to 
LAGB have been described infrequently [97, 98] because both are purely restrictive 
procedures and prone to the same complications. The conversion from VBG to BPD 
is difficult because of the presence of a vertical stapler line but has been described in 
literature recently [99]. Conversion form VBG to DS also has been described in a single 
report [79]. Furthermore, the laparoscopic conversion from failed VBG to GSR has been 
reported but with poor results including a complication rate of 17% and 84% and a re-
operation rate of 5% and 33% [100, 101]. In chapter 3.1, results of the conversion from 
VBG to RYGB are described. Follow up was 100% with a mean duration of 38 months. 
A low rate of perioperative complications was found (2%) but long term complications 
occurred in 22.7%, mainly anastomotic stenosis which could be treated by endoscopic 
dilatation. However, re-operations were necessary in 6.9% of cases because of renewed 
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weight gain. Weight loss was successful with a decrease in BMI of 10.4 kg/m² which 
is consistent with the literature (decrease in BMI of 8 to 11 kg/m²) [87, 88, 102-106]. 
The conversion to RYGB was also successful in patients with specific upper abdominal 
complaints which all decreased afterwards. 
In conclusion, VBG is a successful operation in terms of weight loss but the failure rate 
is too high and it should not be performed anymore. The only evidence-based option in 
case of failure is conversion to RYGB which has good results on weight loss, patients’ 
symptoms and has a low re-operation rate. 
Endoscopic treatment
As a reaction to the high failure rate of restrictive procedures, the necessity of re-
operations and the procedure-specific complications of malabsorptive bariatric 
operations many new techniques and devices are being developed. The ultimate goal is 
a minimally invasive technique with a low morbidity rate, no long term complications and 
a good and durable effect on weight and comorbidities. Apart from new laparoscopic 
techniques a whole variety of endoscopic procedures is now available which are 
described in chapter 4.1. Transoral gastroplasty is a technique where endoscopically 
guided staplers are placed and used to create a stapled restrictive pouch along the 
lesser curve of the stomach. Recently, the results of 21 patients treated with transoral 
gastroplasty were published by Deviere et al. Excess weight loss after this procedure 
was 22.6% and 24.4% after 3 and 6 months, respectively. However, 11 of 21 patients 
developed a stapler line failure during follow up. The most frequently reported adverse 
events were nausea, vomiting and pain [107]. Especially the side-effects of this technique 
are comparable with VBG. Therefore, the practical and widespread use of transoral 
gastroplasty in the future is highly questionable. Endoscopic botulinum toxin injection 
in the gastric antrum and fundus is another possibility and has been investigated by 
Foschi et al in a randomized, double-blind study. Weight loss with a decrease in BMI of 
4 kg/m² was promising although follow up period was only 8 weeks. No complications 
occurred during the procedure and no adverse events were reported. Because of the 
known temporary effect of botulinum longer follow up studies are necessary to draw any 
conclusions about the use of this technique [108]. Another minimally invasive option is 
laparoscopic implantable gastric stimulation (gastric pacing) and several reports have 
been published with favourable results. Excess weight loss after 1 year was 23.8% to 
26.6% in the studies by Favretti et al. and Bohdjalian et al. No severe postoperative 
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complications were reported. However, these studies included only 13 and 9 cases, 
respectively [109, 110]. A larger patient group is described by Miller et al. reporting 91 
patients with a follow up period of 2 years. Mean excess weight loss was 25% after 1 
year and 20% after 2 years [111]. However, recently published results of a randomized 
sham-controlled trial showed no benefit of gastric pacing after 12 months [112]. Finally, 
results of the endoscopically placed intragastric balloon were recently described in 
a review by Mathus – Vliegen et aI. In randomized trials, weight loss of 16 to 21 kg 
was obtained after 6 months. Failure rate after balloon placement, described as no or 
insufficient weight loss, was 15.3% while intolerance of the balloon with removal as a 
consequence was reported in 6.7% [113]. In chapter 4.2, a new minimally invasive, 
endoscopically placed device was investigated. The duodenal-jejunal bypass sleeve 
(DJBS; EndoBarrier Gastrointestinal Liner, GI Dynamics, Inc, Lexington, Massachusetts, 
USA) is a single use endoscopic implant mimicking a duodenal-jejunal bypass. The 
device is comprised of a nitinol anchor, which is used to reversibly affix the device to the 
wall of the duodenum, and an impermeable fluoropolymer sleeve extending 60 cm into 
the small bowel. The anchor is located in the duodenal bulb and the sleeve stretches out 
into the duodenum and partially into the jejunum. As a result, pancreatic and bile juices 
will mix with the food only after the sleeve which may induce malabsorption and creates 
a bypass of the proximal intestinal tract. 
Feasibility studies in animals and humans have been published. Two animal-based 
(porcine) studies showed a good patency of the device and acceptable tissue response 
while weight loss was better in treated animals compared to sham-treated animals 
[114]. The first 2 human studies described a safe delivery and subsequent removal 
of the device [115, 116]. In the present thesis the first European experience with the 
device is described. Thirty device patients were included and compared to 11 control 
patients. Four devices could not be placed because of technical problems. No severe 
adverse events occurred. Post-implant nausea (76.9%) and abdominal pain (50%) were 
the most frequently reported mild adverse events and occurred only in the first week 
after implantation. Four devices had to be removed early because of sleeve obstruction 
(1), migration (2) and unexplained abdominal pain (1).  Weight loss after 12 weeks 
was respectively 19.0% and 6.9% for the device group and control group while 88% 
of patients in the device group lost more than 10% of their excess weight. Comparison 
of these results with the other minimally invasive techniques is difficult because of 
differences in weight loss parameters, follow up period and definition of failure. However, 
with an EWL of 19% and a failure rate of 15.3% compared to 20% - 26.6% and 15.3% 
- 52%, as described in the available literature of the other techniques, the device is 
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promising. Furthermore, because of the theoretical impact on diabetes mellitus caused 
by the foregut exclusion (duodenum bypass), the DJBS has gained interest not only for 
its potential role in weight loss but also in the treatment of T2DM. Recently, a number 
of studies have investigated the role of foregut exclusion in the treatment of obesity and 
specifically in combination with T2DM. Observational studies of RYGB patients have 
shown an early improvement of T2DM after the operation when weight loss was not 
yet achieved [117, 118]. Studies by Rubino et al. prove that bypassing a short segment 
of proximal intestine causes a rapid improvement of glucose homeostasis in diabetic 
rats, independently of food intake, body weight, malabsorption or nutrient delivery to 
the more distal bowel. The mechanism behind this phenomenon lies in the intestinal 
hormones produced in the duodenum and the proximal jejunum (foregut exclusion 
theory). Involved hormones are glucose-dependent insulinotropic polypeptide, which 
has a positive effect on insulin production and sensitivity and cholecystokinin, which 
influences satiety as well as insulin production [6]. Another theory is that the delivery of 
undigested nutrients to the more distal bowel could also cause an improvement in T2DM 
patients (hindgut theory) caused by elevation of the intestinal hormones produced in the 
ileum. These hormones, glucagon like peptide-1 and peptide YY, cause improvement 
of diabetes and obesity by stimulating the growth of beta cell mass and inducing satiety 
[7-9]. The design and position of the DJBS, with a small but specific part of excluded 
intestine, suggests that bypassing the duodenum is more important than the delivery of 
undigested nutrients to the ileum. In the study, described in chapter 4.2, 8 patients had 
diabetes in the device group. Improvement was observed in 6 patients and resolution 
in one patient. These 7 patients were able to significantly lower insulin dosages and 
oral medication. Mean fasting glucose levels before the device placement and after 
12 weeks were, respectively, 11.1 mmol/L and 9.3 mmol/L. HbA1c levels decreased in 
the same period from 8.8% to 7.7%. In our opinion this is the most interesting feature 
of the DJBS. Because of the epidemic of T2DM, also in the non-obese population, 
treating therapy-resistant or severe T2DM patients with bariatric procedures is now 
being discussed. If the DJBS is capable of successfully treating and curing T2DM it 
would be preferable to a more invasive procedure. However, more research has to be 
performed focusing specifically on T2DM and long term results. 
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Conclusion
Good and durable results can be achieved with restrictive bariatric procedures 
although this success comes with a price. The percentage of failures and necessary 
re-operations after VBG is unacceptably high and therefore this procedure should not 
be performed anymore. In case of a failure the conversion to RYGB is a good option 
with excellent results on patients’ weight loss, decrease in comorbidities and symptoms. 
Long term success can be achieved with the LAGB but a certain amount of revisional 
procedures will have to be taken into account. However, these re-operations in the 
form of refixation of the band or a conversion to RYGB are successful and have a low 
mortality and acceptable morbidity. A complete and durable follow up after all bariatric 
procedures and revisions is mandatory in order to achieve long term success. Because 
of the complications of the current bariatric procedures future research should focus on 
the development of minimally invasive but still successful techniques and devices. The 
DJBS is an example of a promising new technique which should be investigated more 
thoroughly especially because of the interesting effects on T2DM. 
The future of bariatric surgery will be exciting and full of discoveries about morbid obesity 
and its related metabolic disorders. From around the world, medical professionals and 
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Het doel van dit promotie onderzoek is het beschrijven van de klinische resultaten 
van bariatrische operaties. Deze operaties worden verdeeld in twee groepen, te 
weten restrictieve en malabsorptieve ingrepen. Voorbeelden van puur restrictieve 
operaties zijn de laparoscopische aanpasbare maagband (LAMB) en de verticale 
maagverkleining (VMV). Daar tegenover staan de grotendeels malabsorptieve ingrepen 
als de biliopancreatische diversie (BPD) volgens Scopinaro en de duodenal switch 
(DS). Hoewel de bariatrische chirurgie is begonnen met malabsorptieve ingrepen 
zijn de meeste hiervan verlaten door het grote aantal complicaties [1]. Restrictieve 
operaties zijn minder complicatie gevoelig en veroorzaken tevens minder mineralen- 
en vitaminetekorten. De huidige meest toegepaste ingrepen zijn de LAMB en de 
(laparoscopische) maagomleiding (MO). De laatste techniek is een mengvorm van een 
restrictieve en malabsorptieve ingreep. Het werkingsmechanisme van de LAMB berust 
vooral op voedselrestrictie terwijl de LMO behalve restrictie ook een effect heeft op 
de hormoonhuishouding van het duodenum doordat dit orgaan wordt uitgeschakeld 
van de voedselstroom. Dit op zichzelf heeft een belangrijke en gunstige invloed op 
de glucoseregulatie bij patiënten met type 2 diabetes mellitus (T2DM) [2]. Hoewel 
er nog veel onduidelijk is over het werkingsmechanisme van bariatrische ingrepen 
is evident aangetoond dat de operaties significant en langdurig gewichtsverlies 
bewerkstelligen. Tevens veroorzaken de operaties een verbetering of zelfs genezing 
van met obesitas gerelateerde ziekten als T2DM, hart- en vaatziekten, slaap apneu 
syndroom, gewrichtsklachten en bepaalde soorten kanker [3, 4]. Ook de kwaliteit van 
leven verbetert aanzienlijk en langdurig na de operatie [5-7]. Dit effect wordt bevestigd 
in het huidige onderzoek en beschreven in hoofdstuk 2.2. Omdat deze verbeteringen 
optreden na alle operaties en de verschillen in de loop van de jaren verdwijnen is 
het niet alleen belangrijk om de operaties te beoordelen op deze parameters. Juist 
de onderscheidende factoren als lange termijn complicaties en re-operaties zouden 
meer aandacht moeten krijgen in toekomstig onderzoek. Dit promotie onderzoek is 
vooral gericht op de lange termijn resultaten, complicaties en re-operaties na de meest 
gebruikelijke operaties. Tevens wordt aandacht besteed aan nieuwe technieken welke 
minder invasief zijn en mogelijk minder complicaties veroorzaken. 
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Resultaten van de laparoscopische aanpasbare maagband
In hoofdstuk 2.1 worden de lange termijn resultaten van de LAMB beschreven. Het 
gewichtsverlies na 7 jaar is goed en vergelijkbaar met de beschreven literatuur [8-10]. 
Uitgedrukt in %excess weight loss (%EWL; de mate van overgewicht wat de patiënt 
heeft verloren) bedraagt dit 54%. Echter, dit succes gaat gepaard met vele noodzakelijke 
re-operaties gedurende de follow-up. Als gevolg van onder andere uitzetten van 
de maagpouch en “slippen” van de band moesten 44% van de patiënten opnieuw 
geopereerd worden na een gemiddelde periode van 3 jaar. Door een verbetering van 
techniek, de leercurve en betere kwaliteit van de banden daalt het aantal re-operaties 
de laatste jaren aanzienlijk [11, 12]. In de literatuur worden getallen van 2% re-operaties 
genoemd [13]. Een aantal factoren is echter zeer belangrijk bij het analyseren van deze 
getallen. De follow-up moet compleet en langdurig zijn om betrouwbare gegevens op te 
leveren. Gezien het feit dat de gemiddelde tijd tussen de eerste en de tweede operatie 
in deze studie 3 jaar was is een follow-up periode van minimaal 3 jaar maar bij voorkeur 
5 jaar noodzakelijk om iets te kunnen zeggen over re-operaties. In hoofdstuk 2.1 wordt 
een follow-up van 7 jaar beschreven van 91% van de patiënten. Deze getallen kunnen 
derhalve als betrouwbaar worden beschouwd. 
Wanneer er een complicatie optreedt na de LAMB zijn er verschillende opties. Allereerst 
moet getracht worden de band te behouden door deze te refixeren of eventueel te 
vervangen. Deze optie wordt besproken in hoofdstuk 3.2. Een laparoscopische refixatie 
van de band is een succesvolle ingreep aangezien de patiënten na deze re-operatie 
opnieuw gewicht verloren en het aantal complicaties laag was. Er moet echter wel 
rekening worden gehouden met de soort complicatie van de band welke de re-operatie 
noodzakelijk maakt. Patiënten met puur technisch falen van de band die daarvoor met de 
band een bevredigend gewichtsverlies hadden bereikt kunnen goed geholpen worden 
met een refixatie. Is er echter sprake van therapieontrouw of een onvoldoende effect van 
de band, dan kan er mogelijk beter worden gekozen voor het omzetten van de LAMB 
naar een ander soort bariatrische operatie. Deze verschillende vormen van conversie 
worden beschreven in hoofdstuk 3.3. Hieruit blijkt dat een refixatie van de band of een 
conversie naar een MO de beste opties zijn in het geval van een complicatie na een 
LAMB. De keuze tussen deze twee opties berust op de eerder genoemde factoren. Een 
conversie naar meer ingewikkelde malabsorptieve ingrepen verdient niet de voorkeur 
omdat het gewichtsverlies niet significant beter is en er wel meer complicaties optreden. 
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Concluderend is de LAMB een succesvolle operatie op de lange termijn met bevredigend 
gewichtsverlies. Complicaties welke een re-operatie noodzakelijk maken komen veel 
voor maar zijn goed te behandelen met ofwel een refixatie van de band ofwel een 
conversie naar een MO. 
Resultaten van de verticale maagverkleining
In hoofdstuk 2.1 worden de lange termijn resultaten van de VMV beschreven. Het 
gewichtsverlies na 7 jaar is goed met 69% EWL en zelfs beter dan de beschreven 
literatuur [8, 9, 14]. Echter, dit succes gaat gepaard met een hoog faalpercentage 
gedurende de follow-up [15-18]. Het opnieuw uitvoeren van een VMV na een 
complicatie is niet succesvol en daarom dient altijd een conversie naar bijvoorbeeld 
een MO te worden uitgevoerd [17]. In de huidige studie was dit noodzakelijk bij 65% van 
de patiënten na een gemiddelde follow-up van 7 jaar. De VMV dient dan ook niet meer 
uitgevoerd te worden ondanks het succesvolle gewichtsverlies op de lange termijn. Het 
aantal complicaties en re-operaties wordt te hoog geacht. 
In het geval van een complicatie na een VMV, bijvoorbeeld het loslaten van de nietjesrij 
of een uitgangsstenose, kan een conversie na een andere bariatrische ingreep worden 
overwogen. Conversies naar LAMB, BPD en DS zijn in de literatuur weinig beschreven 
en over het algemeen gecompliceerd [19-22]. De conversie naar een MO is de meest 
logische keuze en wordt beschreven in hoofdstuk 3.1. Hoewel de conversie gepaard 
gaat met een significant aantal complicaties (22.7%) wordt deze toch als succesvol 
beschouwd aangezien het gewicht verder daalt en het aantal re-operaties nadien laag 
is. Verder blijken de resultaten onafhankelijk te zijn van de reden van de conversie 
onderverdeeld in gewichtstoename, extreem gewichtsverlies of gastro-intestinale 
klachten. 
Concluderend is de VMV op de lange termijn een succesvolle operatie qua gewichtsverlies 
maar dient niet meer uitgevoerd te worden omdat het aantal complicaties te hoog is. 





Als reactie op de lange termijn complicaties en re-operaties na restrictieve ingrepen en 
de procedurespecifieke problemen van de malabsorptieve ingrepen zijn er vele nieuwe 
technieken ontwikkeld. Idealiter is dit een minimaal invasieve techniek met weinig 
complicaties en een langdurig effect op gewicht en obesitas-gerelateerde ziekten. 
Behalve de ontwikkelingen in de laparoscopische chirurgie is er ook veel aandacht voor 
endoscopische technieken. Transorale gastroplastiek, endoscopische botuline injectie 
en maagstimulatie middels “pacing” zijn hier voorbeelden van [23-26]. In hoofdstuk 4.1 
wordt een nieuwe endoscopische techniek beschreven. De duodenal-jejunal bypass 
sleeve (DJBS; EndoBarrier Gastrointestinal Liner, GI Dynamics, Inc, Lexington, 
Massachusetts, USA) is een gastroscopisch ingebrachte fluoropolymere sleeve welke 
wordt gefixeerd in de bulbus duodeni en over 60 cm de wand van duodenum en jejunum 
bedekt. Het gevolg is dat er geen contact is tussen het voedsel en de darmwand. 
Behalve dat dit een omleidingseffect heeft vergelijkbaar met MO is er tevens een effect 
op de hormoonhuishouding van het duodenum. Dit blijkt uit de snelle verbetering van 
T2DM na implantatie van de sleeve. In de literatuur zijn enkele dierexperimentele 
studies en de eerste menselijke implantaties beschreven [27-31]. In hoofdstuk 4.2 wordt 
de eerste Europese studie met de DJBS beschreven. Op een totaal van 30 implantaties 
konden er 4 niet worden uitgevoerd door technische problemen. Gedurende de follow-
up werden er 4 devices verwijderd als gevolg van complicaties. Het gewichtsverlies 
was 19.0% EWL en dit was significant hoger dan in de controle groep welke alleen een 
dieet volgde (6.9%). Verder werd specifiek aandacht besteed aan de patiënten met 
T2DM (8 in de device groep) gezien het omleidingseffect van de DJBS. Zes patiënten 
merkten een verbetering op; dat wil zeggen zij hoefden minder insuline te gebruiken 
en hun glucose en HbA1c waardes verlaagden. Een patiënt gebruikte zelfs helemaal 
geen medicatie meer. Gezien het wereldwijd toenemende probleem van T2DM, vaak 
gepaard gaande met overgewicht, is dit mogelijk de belangrijkste eigenschap van de 
DJBS. Specifieke studies naar het werkingsmechanisme van de DJBS en het effect op 
T2DM zijn echter noodzakelijk. Deze studies worden op dit moment in onder andere 




Restrictieve bariatrische ingrepen zijn succesvol op de lange termijn. Echter, het aantal 
complicaties en re-operaties na VMV is onacceptabel hoog. Deze operatie dient niet 
meer uitgevoerd te worden. Patiënten met een complicatie na een VMV zijn het beste 
geholpen met een conversie naar een MO. Het lange termijn succes van de LAMB 
gaat ook gepaard met een significant aantal re-operaties. In dit geval kan vaak worden 
volstaan met een refixatie van de band of een conversie naar een MO, afhankelijk van 
de indicatie tot re-operatie. Deze ingrepen hebben een laag complicatie percentage en 
zijn zeer succesvol. Derhalve is de LAMB een succesvolle bariatrische operatie en een 
goede eerste keuze voor morbide obese patiënten. Gezien het aantal complicaties op 
de lange termijn na alle ingrepen dienen alle patiënten langdurig in follow-up te blijven. 
Tevens zal er verder onderzoek moeten worden gedaan naar nieuwe minimaal invasieve 
technieken gepaard gaande met minder complicaties. De DJBS is een voorbeeld van 
een veelbelovende techniek met een opvallend effect op T2DM. 
Bariatrische chirurgie heeft de toekomst. Als gevolg van deze operaties zal meer kennis 
worden vergaard over morbide obesitas en alle aan obesitas-gerelateerde ziekten. 





1. Deitel, M., A synopsis of the development of bariatric operations. Obes Surg, 2007. 17(6): 
p. 707-10.
2. Rubino, F., et al., The mechanism of diabetes control after gastrointestinal bypass surgery 
reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann 
Surg, 2006. 244(5): p. 741-9.
3. Bjorntorp, P., Results of conservative therapy of obesity: correlation with adipose tissue 
morphology. Am J Clin Nutr, 1980. 33(2 Suppl): p. 370-5.
4. Fisher, B.L. and P. Schauer, Medical and surgical options in the treatment of severe obesity. 
Am J Surg, 2002. 184(6B): p. 9S-16S.
5. van Gemert, W.G., et al., Quality of life assessment of morbidly obese patients: effect of 
weight-reducing surgery. Am J Clin Nutr, 1998. 67(2): p. 197-201.
6. Nguyen, N.T., et al., Laparoscopic versus open gastric bypass: a randomized study of out-
comes, quality of life, and costs. Ann Surg, 2001. 234(3): p. 279-89; discussion 289-91.
7. Hell, E., et al., Evaluation of health status and quality of life after bariatric surgery: compari-
son of standard Roux-en-Y gastric bypass, vertical banded gastroplasty and laparoscopic 
adjustable silicone gastric banding. Obes Surg, 2000. 10(3): p. 214-9.
8. Nilsell, K., et al., Prospective randomised comparison of adjustable gastric banding and 
vertical banded gastroplasty for morbid obesity. Eur J Surg, 2001. 167(7): p. 504-9.
9. Miller, K., A. Pump, and E. Hell, Vertical banded gastroplasty versus adjustable gastric 
banding: prospective long-term follow-up study. Surg Obes Relat Dis, 2007. 3(1): p. 84-90.
10. O’Brien, P.E. and J.B. Dixon, Lap-band: outcomes and results. J Laparoendosc Adv Surg 
Tech A, 2003. 13(4): p. 265-70.
11. O’Brien, P.E., et al., A prospective randomized trial of placement of the laparoscopic adjust-
able gastric band: comparison of the perigastric and pars flaccida pathways. Obes Surg, 
2005. 15(6): p. 820-6.
12. Weiner, R., et al., A prospective randomized trial of different laparoscopic gastric banding 
techniques for morbid obesity. Surg Endosc, 2001. 15(1): p. 63-8.
13. Blanc, P.M., et al., Preliminary results of the laparoscopic adjustable gastric banding proce-
dure by a new generation of silicone band: MIDBAND. Obes Surg, 2008. 18(5): p. 569-72.
14. Balsiger, B.M., et al., Ten and more years after vertical banded gastroplasty as primary 
operation for morbid obesity. J Gastrointest Surg, 2000. 4(6): p. 598-605.
15. Sugerman, H.J., et al., Conversion of failed or complicated vertical banded gastroplasty to 
gastric bypass in morbid obesity. Am J Surg, 1996. 171(2): p. 263-9.
16. Gonzalez, R., et al., Operative technique for converting a failed vertical banded gastroplasty 
to Roux-en-Y gastric bypass. J Am Coll Surg, 2005. 201(3): p. 366-74.
17. van Gemert, W.G., et al., Revisional surgery after failed vertical banded gastroplasty: res-
toration of vertical banded gastroplasty or conversion to gastric bypass. Obes Surg, 1998. 
8(1): p. 21-8.
18. MacLean, L.D., B.M. Rhode, and R.A. Forse, Late results of vertical banded gastroplasty for 
morbid and super obesity. Surgery, 1990. 107(1): p. 20-7.
19. Thill, V., et al., Laparoscopic gastric banding as revisional procedure to failed vertical gas-
troplasty. Obes Surg, 2009. 19(11): p. 1477-80.
20. Taskin, M., et al., Conversion of failed vertical banded gastroplasty to open adjustable gas-
tric banding. Obes Surg, 2001. 11(6): p. 731-4.
21. Daskalakis, M., et al., Conversion of failed vertical banded gastroplasty to biliopancreatic 
diversion, a wise option. Obes Surg, 2009. 19(12): p. 1617-23.
180
CHAPTER 5
22. Dapri, G., G.B. Cadiere, and J. Himpens, Laparoscopic conversion of adjustable gastric 
banding and vertical banded gastroplasty to duodenal switch. Surg Obes Relat Dis, 2009. 
5(6): p. 678-83.
23. Deviere, J., et al., Safety, feasibility and weight loss after transoral gastroplasty: First human 
multicenter study. Surg Endosc, 2008. 22(3): p. 589-98.
24. Favretti, F., et al., Treatment of morbid obesity with the Transcend Implantable Gastric Stim-
ulator (IGS): a prospective survey. Obes Surg, 2004. 14(5): p. 666-70.
25. Foschi, D., et al., Treatment of morbid obesity by intraparietogastric administration of botu-
linum toxin: a randomized, double-blind, controlled study. Int J Obes (Lond), 2007. 31(4): p. 
707-12.
26. Bohdjalian, A., et al., One-year experience with Tantalus: a new surgical approach to treat 
morbid obesity. Obes Surg, 2006. 16(5): p. 627-34.
27. Tarnoff, M., S. Shikora, and A. Lembo, Acute technical feasibility of an endoscopic duode-
nal-jejunal bypass sleeve in a porcine model: a potentially novel treatment for obesity and 
type 2 diabetes. Surg Endosc, 2008. 22(3): p. 772-6.
28. Rodriguez-Grunert, L., et al., First human experience with endoscopically delivered and 
retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis, 2008. 4(1): p. 55-9.
29. Tarnoff, M., et al., Chronic in-vivo experience with an endoscopically delivered and retrieved 
duodenal-jejunal bypass sleeve in a porcine model. Surg Endosc, 2008. 22(4): p. 1023-8.
30. Tarnoff, M., L.M. Kaplan, and S. Shikora, An evidenced-based assessment of preoperative 
weight loss in bariatric surgery. Obes Surg, 2008. 18(9): p. 1059-61.
31. Gersin, K.S., et al., Duodenal- jejunal bypass sleeve: a totally endoscopic device for the 
treatment of morbid obesity. Surg Innov, 2007. 14(4): p. 275-8.
